We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$59.8B
AUM Growth
+$5.07B
(+9.3%)
Cap. Flow
+$518M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,358
Reduced
537
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$68M |
| 2 |
Truist Financial
TFC
|
+$55.9M |
| 3 |
ServiceNow
NOW
|
+$33.3M |
| 4 |
Uber
UBER
|
+$21.4M |
| 5 |
Las Vegas Sands
LVS
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$119M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$55.9M |
| 3 |
Apple
AAPL
|
+$48.3M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$22M |
| 5 |
VIAB
Viacom Inc. Class B
VIAB
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Financials | 15.53% |
| 3 | Healthcare | 13.38% |
| 4 | Consumer Discretionary | 10.07% |
| 5 | Industrials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PACD
2801
DELISTED
Pacific Drilling S.A. Common Shares
PACD
| $160K | ﹤0.01% |
39,128
+393
| +1% | +$1.23K |
|
2802
Seres Therapeutics
MCRB
$51.9M
| $158K | ﹤0.01% |
2,297
+180
| +9% | +$13.3K |
|
|
MPX
2803
DELISTED
Marine Products Corp
MPX
| $158K | ﹤0.01% |
10,967
-73
| -0.7% | -$1.06K |
|
|
TCRR
2804
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $158K | ﹤0.01% |
11,068
+278
| +3% | +$4.3K |
|
|
CMRX
2805
DELISTED
Chimerix, Inc.
CMRX
| $157K | ﹤0.01% |
77,435
-9,933
| -11% | -$18.3K |
|
|
FNCB
2806
DELISTED
FNCB Bancorp Inc. Common Stock
FNCB
| $155K | ﹤0.01% |
18,329
+502
| +3% | +$3.95K |
|
|
CSLT
2807
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| $155K | ﹤0.01% |
116,458
+1,314
| +1% | +$1.83K |
|
2808
Gencor Industries
GENC
$214M
| $154K | ﹤0.01% |
13,211
+22
| +0.2% | +$265 |
|
2809
Senseonics Holdings Inc
SENS
$282M
| $154K | ﹤0.01% |
8,403
+848
| +11% | +$16.7K |
|
|
AFMD
2810
DELISTED
Affimed
AFMD
| $152K | ﹤0.01% |
5,553
+478
| +9% | +$12.8K |
|
2811
Sutro Biopharma
STRO
$428M
| $152K | ﹤0.01% |
1,380
+22
| +2% | +$2.27K |
|
|
SRT
2812
DELISTED
Startek Inc.
SRT
| $152K | ﹤0.01% |
19,100
-139
| -0.7% | -$1.01K |
|
|
VAPO
2813
DELISTED
Vapotherm, Inc. Common Stock
VAPO
| $151K | ﹤0.01% |
1,555
+68
| +5% | +$5.74K |
|
2814
Cytosorbents Corp
CTSO
$24.3M
| $149K | ﹤0.01% |
38,734
+207
| +0.5% | +$903 |
|
|
GCAP
2815
DELISTED
Gain Capital Holdings, Inc.
GCAP
| $149K | ﹤0.01% |
37,769
+1,128
| +3% | +$4.85K |
|
2816
Amplify Energy
AMPY
$166M
| $148K | ﹤0.01% |
22,339
-68
| -0.3% | -$438 |
|
2817
Crawford & Co Class A
CRD.A
$607M
| $148K | ﹤0.01% |
12,912
+443
| +4% | +$4.83K |
|
2818
IDT Corp
IDT
$1.66B
| $148K | ﹤0.01% |
20,571
+200
| +1% | +$1.44K |
|
2819
Spero Therapeutics
SPRO
$70.6M
| $148K | ﹤0.01% |
15,387
+345
| +2% | +$3.72K |
|
2820
Marchex
MCHX
$83.3M
| $147K | ﹤0.01% |
38,976
+1,081
| +3% | +$3.89K |
|
|
PBPB
2821
DELISTED
Potbelly
PBPB
| $147K | ﹤0.01% |
34,782
+160
| +0.5% | +$698 |
|
2822
Celsius Holdings
CELH
$7.6B
| $145K | ﹤0.01% |
90,171
+2,310
| +3% | +$3.07K |
|
2823
FS KKR Capital
FSK
$3.23B
| $145K | ﹤0.01% |
5,916
| – | – |
|
2824
Gaia
GAIA
$48.9M
| $145K | ﹤0.01% |
18,098
-705
| -4% | -$5.45K |
|
|
MRNS
2825
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $145K | ﹤0.01% |
16,726
+626
| +4% | +$3.51K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
- RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
- RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
- RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
- RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
- RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
- RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.